Health & Fitness
Thu, May 10, 2012
LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Synageva BioPharma Corp. ] (aSynagevaa) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, will present at the upcoming Bank of America Merrill Lynch 2012 Health Care Conference being held in Las Vegas, Nevada.
Sanj K. Patel, President and Chief Executive Officer of Synageva, is scheduled to present on Wednesday, May 16, 2012, at 10:40 a.m. PDT (1:40 p.m. EDT). The presentation will be webcast live and may be accessed from the aWebcasts & Presentationsa section of the Investor Relations tab on the home page of Synagevaas website at [ www.synageva.com ].
About Synagevaas Lead Program
[ SBC-102 ] is being developed as an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD), and is a recombinant form of the human LAL enzyme. SBC-102 is currently being evaluated in global clinical trials and has been granted orphan designations by the U.S. Food and Drug Administration (aFDAa) and the European Medicines Agency. Additionally, SBC-102 received fast track designation by the FDA.
About LAL Deficiency
[ Lysosomal Acid Lipase Deficiency ] is a rare, autosomal recessive lysosomal storage disorder (LSD) that is caused by a marked decrease in LAL enzyme activity. Late onset LAL Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In these patients, the buildup of fatty material in the liver, spleen and blood vessel walls leads to complications resulting in significant morbidity and mortality. Early onset LAL Deficiency, sometimes called Wolman Disease, affects infants in the first year of life and is characterized by growth failure, malabsorption, steatorrhea and hepatomegaly and is rapidly fatal, usually within the first year of life.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Synageva has several protein therapeutics in its [ pipeline ]. The company has assembled a team with a proven record of bringing orphan therapies to patients.
Further information regarding Synageva BioPharma Corp. is available at [ www.synageva.com ].